Mark S. Levine Immunovant, Inc. (IMVT) insider trading activity

Mark S. Levine is Chief Legal Officer of Immunovant, Inc.. Currently has a direct ownership of 319,228 shares of IMVT, which is worth approximately $8.78 Million. The most recent transaction as insider was on Nov 20, 2024, when has been sold 3,650 shares (Common Stock) at a price of $25.45 per share, resulting in proceeds of $92,892. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 319K

0% 3M change

6.97% 12M change

Total Value Held $8.78 Million

Mark S. Levine Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 20 2024	SELL Open market or private sale	$92,892 $25.45 p/Share	3,650 Reduced 1.13%	319,228 Common Stock
Oct 23 2024	SELL Open market or private sale	$128,780 $29.53 p/Share	4,361 Reduced 1.33%	322,878 Common Stock
Oct 16 2024	SELL Open market or private sale	$82,339 $28.79 p/Share	2,860 Reduced 0.87%	327,239 Common Stock
Aug 21 2024	SELL Open market or private sale	$105,703 $32.08 p/Share	3,295 Reduced 0.99%	330,099 Common Stock
Jul 24 2024	SELL Open market or private sale	$111,456 $27.76 p/Share	4,015 Reduced 1.19%	333,394 Common Stock
Jul 17 2024	SELL Open market or private sale	$75,375 $30.09 p/Share	2,505 Reduced 0.74%	337,409 Common Stock
May 22 2024	SELL Open market or private sale	$96,125 $29.65 p/Share	3,242 Reduced 0.94%	339,914 Common Stock
Apr 24 2024	SELL Open market or private sale	$114,530 $28.9 p/Share	3,963 Reduced 1.14%	343,156 Common Stock
Apr 17 2024	SELL Open market or private sale	$288,618 $29.37 p/Share	9,827 Reduced 2.75%	347,119 Common Stock
Apr 02 2024	BUY Grant, award, or other acquisition	-	54,978 Added 13.35%	356,946 Common Stock
Feb 22 2024	SELL Open market or private sale	$77,144 $36.15 p/Share	2,134 Reduced 0.7%	301,968 Common Stock
Jan 26 2024	SELL Open market or private sale	$115,570 $38.18 p/Share	3,027 Reduced 0.99%	304,102 Common Stock
Nov 22 2023	SELL Open market or private sale	$107,771 $33.14 p/Share	3,252 Reduced 1.05%	307,129 Common Stock
Oct 25 2023	SELL Open market or private sale	$142,348 $34.66 p/Share	4,107 Reduced 1.31%	310,381 Common Stock
Aug 24 2023	SELL Open market or private sale	$252,968 $20.59 p/Share	12,286 Reduced 3.76%	314,488 Common Stock
Jul 26 2023	SELL Open market or private sale	$84,724 $21.63 p/Share	3,917 Reduced 1.18%	326,774 Common Stock
Apr 25 2023	SELL Open market or private sale	$42,891 $16.29 p/Share	2,633 Reduced 0.79%	330,691 Common Stock
Apr 12 2023	BUY Grant, award, or other acquisition	-	87,664 Added 20.82%	333,324 Common Stock
Jan 26 2023	SELL Open market or private sale	$187,987 $18.51 p/Share	10,156 Reduced 3.97%	245,660 Common Stock
Aug 17 2022	BUY Grant, award, or other acquisition	-	112,816 Added 30.6%	255,816 Common Stock
Jan 28 2022	BUY Grant, award, or other acquisition	-	143,000 Added 50.0%	143,000 Common Stock

Also insider at

FLXN

Flexion Therapeutics Inc

General Counsel

MSL

Mark S. Levine

Chief Legal Officer

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IMVT shares.

Notify only if

Value

Insider Trading

Get notified when an Immunovant, Inc. insider buys or sells IMVT shares.

Notify only if

Operation

Value

Type

News

Receive news related to Immunovant, Inc.

Track Activities on IMVT

Account